Skip to main content
The common F2 c.20210G>A mutation is associated with elevated prothrombin levels, which promotes development of fibrin clots. 2-4 % of the population is heterozygous for this mutation. Heterozygotes may have an estimated 3-11 fold increased risk of thrombosis. The risk of recurrence venous thrombosis recurrence is higher in individuals who also carry other thrombosis risk factors.
Seattle Children’s provides healthcare without regard to race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry) or disability. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.
© 1995-2014 Seattle Children’s Hospital